Zymeworks to Present at Upcoming November 2018 Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.

The Company will provide a corporate update at the Stifel Healthcare Conference on Tuesday, November 13, 2018 at 8:00 a.m. ET and at the Jefferies Healthcare Conference on Wednesday, November 14, 2018 at 2:40 p.m. GMT (9:40 a.m. ET).

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005175/en/